Corpus
Accueil
Racine
Corpus
Exploration
Accueil
Racine
Accueil

Serveur d'exploration COVID et hydrochloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.

Identifieur interne : 000C64 ( Main/Corpus ); précédent : 000C63; suivant : 000C65

Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.

Auteurs : Gabriella D'Ettorre ; Gregorio Recchia ; Marco Ridolfi ; Guido Siccardi ; Claudia Pinacchio ; Giuseppe Pietro Innocenti ; Letizia Santinelli ; Federica Frasca ; Camilla Bitossi ; Giancarlo Ceccarelli ; Cristian Borrazzo ; Guido Antonelli ; Carolina Scagnolari ; Claudio Maria Mastroianni

Source :

RBID : pubmed:32899009

English descriptors

Abstract

RATIONALE

Complex immune dysregulation in interferon (IFN) and T cell response has been observed in human immunodeficiency virus (HIV-1)-infected patients as well as in coronavirus disease-2019 (COVID-19) patients. However, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/HIV-1 coinfection has been described in only few cases worldwide and no data are available on immunological outcomes in HIV-1-patients infected with SARS-CoV-2. Hence, this study aims to compare type I IFN response and T cell activation levels between a SARS-CoV-2/HIV-1-coinfected female patient and age-matched HIV-1-positive or uninfected women.

PATIENT CONCERNS

A 52-year-old woman diagnosed with SARS-CoV-2/HIV-1 coinfection, ten HIV-1-positive women and five age-matched-healthy individuals were enrolled in this study.

DIAGNOSES

SARS-CoV-2 infection caused severe pneumonia in the second week of illness in HIV-1-positive patient under protease inhibitors. Chest high-resolution computed tomography images of the SARS-CoV-2/HIV-1-coinfected patient showed bilateral ground-glass opacities.

INTERVENTIONS

SARS-CoV-2/HIV-1-coinfected female patient under darunavir/cobicistat regimen received a 7-days hydroxychloroquine therapy. Analysis of IFNα/β mRNA levels and CD4 and CD8 T cell (CD38, human leukocyte antigen-DR [HLA-DR], CD38 HLA-DR) frequencies were performed by RT/real-time PCR assays and flow cytometry, respectively. Median relative difference (MRD) was calculated for each immunological variable. For values greater than reference, MRD should be a positive number and for values that are smaller, MRD should be negative.

OUTCOMES

The severe pneumonia observed in SARS-CoV-2/HIV-1-positive patient under protease inhibitors was reversed by a 7-days hydroxychloroquine therapy. At the end of treatment, on day 7, patient reported resolution of fever, normalization of respiratory rate (14 breaths/min), and improved oxygen arterial pressure with a FiO2 of 30%. MRD values for IFNα/β and CD4 and CD8 T cells expressing CD38 and/or HLA-DR found in SARS-CoV-2-/HIV-1-coinfected woman were approximatively equal to 0 when refereed respectively to HIV-1-positive female patients [MRDs IFNα/β: median -0.2545 (range: -0.5/0.1); T cells: median -0.11 (range: -0.8/1.3)] and ≥ 6 when referred to healthy individuals [MRDs IFNα/β: median 28.45 (range: 15/41.9); T cells: median 10 (range 6/22)].

LESSONS

These results indicate that SARS-CoV-2 infection in HIV-1-positive female patient was associated with increased levels of IFNα/β-mRNAs and T cell activation compared to healthy individuals.


DOI: 10.1097/MD.0000000000021803
PubMed: 32899009
PubMed Central: PMC7478511

Links to Exploration step

pubmed:32899009

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.</title>
<author>
<name sortKey="D Ettorre, Gabriella" sort="D Ettorre, Gabriella" uniqKey="D Ettorre G" first="Gabriella" last="D'Ettorre">Gabriella D'Ettorre</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Recchia, Gregorio" sort="Recchia, Gregorio" uniqKey="Recchia G" first="Gregorio" last="Recchia">Gregorio Recchia</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ridolfi, Marco" sort="Ridolfi, Marco" uniqKey="Ridolfi M" first="Marco" last="Ridolfi">Marco Ridolfi</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Siccardi, Guido" sort="Siccardi, Guido" uniqKey="Siccardi G" first="Guido" last="Siccardi">Guido Siccardi</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Pinacchio, Claudia" sort="Pinacchio, Claudia" uniqKey="Pinacchio C" first="Claudia" last="Pinacchio">Claudia Pinacchio</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Innocenti, Giuseppe Pietro" sort="Innocenti, Giuseppe Pietro" uniqKey="Innocenti G" first="Giuseppe Pietro" last="Innocenti">Giuseppe Pietro Innocenti</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Santinelli, Letizia" sort="Santinelli, Letizia" uniqKey="Santinelli L" first="Letizia" last="Santinelli">Letizia Santinelli</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Frasca, Federica" sort="Frasca, Federica" uniqKey="Frasca F" first="Federica" last="Frasca">Federica Frasca</name>
<affiliation>
<nlm:affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Bitossi, Camilla" sort="Bitossi, Camilla" uniqKey="Bitossi C" first="Camilla" last="Bitossi">Camilla Bitossi</name>
<affiliation>
<nlm:affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ceccarelli, Giancarlo" sort="Ceccarelli, Giancarlo" uniqKey="Ceccarelli G" first="Giancarlo" last="Ceccarelli">Giancarlo Ceccarelli</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Borrazzo, Cristian" sort="Borrazzo, Cristian" uniqKey="Borrazzo C" first="Cristian" last="Borrazzo">Cristian Borrazzo</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Antonelli, Guido" sort="Antonelli, Guido" uniqKey="Antonelli G" first="Guido" last="Antonelli">Guido Antonelli</name>
<affiliation>
<nlm:affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</nlm:affiliation>
</affiliation>
<affiliation>
<nlm:affiliation>Microbiology and Virology Unit, Hospital "Policlinico Umberto I", Sapienza University, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Scagnolari, Carolina" sort="Scagnolari, Carolina" uniqKey="Scagnolari C" first="Carolina" last="Scagnolari">Carolina Scagnolari</name>
<affiliation>
<nlm:affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mastroianni, Claudio Maria" sort="Mastroianni, Claudio Maria" uniqKey="Mastroianni C" first="Claudio Maria" last="Mastroianni">Claudio Maria Mastroianni</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32899009</idno>
<idno type="pmid">32899009</idno>
<idno type="doi">10.1097/MD.0000000000021803</idno>
<idno type="pmc">PMC7478511</idno>
<idno type="wicri:Area/Main/Corpus">000C64</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C64</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.</title>
<author>
<name sortKey="D Ettorre, Gabriella" sort="D Ettorre, Gabriella" uniqKey="D Ettorre G" first="Gabriella" last="D'Ettorre">Gabriella D'Ettorre</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Recchia, Gregorio" sort="Recchia, Gregorio" uniqKey="Recchia G" first="Gregorio" last="Recchia">Gregorio Recchia</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ridolfi, Marco" sort="Ridolfi, Marco" uniqKey="Ridolfi M" first="Marco" last="Ridolfi">Marco Ridolfi</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Siccardi, Guido" sort="Siccardi, Guido" uniqKey="Siccardi G" first="Guido" last="Siccardi">Guido Siccardi</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Pinacchio, Claudia" sort="Pinacchio, Claudia" uniqKey="Pinacchio C" first="Claudia" last="Pinacchio">Claudia Pinacchio</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Innocenti, Giuseppe Pietro" sort="Innocenti, Giuseppe Pietro" uniqKey="Innocenti G" first="Giuseppe Pietro" last="Innocenti">Giuseppe Pietro Innocenti</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Santinelli, Letizia" sort="Santinelli, Letizia" uniqKey="Santinelli L" first="Letizia" last="Santinelli">Letizia Santinelli</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Frasca, Federica" sort="Frasca, Federica" uniqKey="Frasca F" first="Federica" last="Frasca">Federica Frasca</name>
<affiliation>
<nlm:affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Bitossi, Camilla" sort="Bitossi, Camilla" uniqKey="Bitossi C" first="Camilla" last="Bitossi">Camilla Bitossi</name>
<affiliation>
<nlm:affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Ceccarelli, Giancarlo" sort="Ceccarelli, Giancarlo" uniqKey="Ceccarelli G" first="Giancarlo" last="Ceccarelli">Giancarlo Ceccarelli</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Borrazzo, Cristian" sort="Borrazzo, Cristian" uniqKey="Borrazzo C" first="Cristian" last="Borrazzo">Cristian Borrazzo</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Antonelli, Guido" sort="Antonelli, Guido" uniqKey="Antonelli G" first="Guido" last="Antonelli">Guido Antonelli</name>
<affiliation>
<nlm:affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</nlm:affiliation>
</affiliation>
<affiliation>
<nlm:affiliation>Microbiology and Virology Unit, Hospital "Policlinico Umberto I", Sapienza University, Rome, Italy.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Scagnolari, Carolina" sort="Scagnolari, Carolina" uniqKey="Scagnolari C" first="Carolina" last="Scagnolari">Carolina Scagnolari</name>
<affiliation>
<nlm:affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mastroianni, Claudio Maria" sort="Mastroianni, Claudio Maria" uniqKey="Mastroianni C" first="Claudio Maria" last="Mastroianni">Claudio Maria Mastroianni</name>
<affiliation>
<nlm:affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Medicine</title>
<idno type="eISSN">1536-5964</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Anti-Retroviral Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>CD4-Positive T-Lymphocytes (metabolism)</term>
<term>CD8-Positive T-Lymphocytes (metabolism)</term>
<term>COVID-19 (MeSH)</term>
<term>Case-Control Studies (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Female (MeSH)</term>
<term>HIV Infections (complications)</term>
<term>HIV Infections (drug therapy)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Interferons (blood)</term>
<term>Lymphocyte Activation (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>RNA, Messenger (MeSH)</term>
<term>Real-Time Polymerase Chain Reaction (MeSH)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Severe Acute Respiratory Syndrome (complications)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Interferons</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Anti-Retroviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Coronavirus Infections</term>
<term>HIV Infections</term>
<term>Pneumonia, Viral</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Coronavirus Infections</term>
<term>HIV Infections</term>
<term>Pneumonia, Viral</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>CD4-Positive T-Lymphocytes</term>
<term>CD8-Positive T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Case-Control Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Lymphocyte Activation</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>RNA, Messenger</term>
<term>Real-Time Polymerase Chain Reaction</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>
<b>RATIONALE</b>
</p>
<p>Complex immune dysregulation in interferon (IFN) and T cell response has been observed in human immunodeficiency virus (HIV-1)-infected patients as well as in coronavirus disease-2019 (COVID-19) patients. However, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/HIV-1 coinfection has been described in only few cases worldwide and no data are available on immunological outcomes in HIV-1-patients infected with SARS-CoV-2. Hence, this study aims to compare type I IFN response and T cell activation levels between a SARS-CoV-2/HIV-1-coinfected female patient and age-matched HIV-1-positive or uninfected women.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>PATIENT CONCERNS</b>
</p>
<p>A 52-year-old woman diagnosed with SARS-CoV-2/HIV-1 coinfection, ten HIV-1-positive women and five age-matched-healthy individuals were enrolled in this study.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>DIAGNOSES</b>
</p>
<p>SARS-CoV-2 infection caused severe pneumonia in the second week of illness in HIV-1-positive patient under protease inhibitors. Chest high-resolution computed tomography images of the SARS-CoV-2/HIV-1-coinfected patient showed bilateral ground-glass opacities.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>INTERVENTIONS</b>
</p>
<p>SARS-CoV-2/HIV-1-coinfected female patient under darunavir/cobicistat regimen received a 7-days hydroxychloroquine therapy. Analysis of IFNα/β mRNA levels and CD4 and CD8 T cell (CD38, human leukocyte antigen-DR [HLA-DR], CD38 HLA-DR) frequencies were performed by RT/real-time PCR assays and flow cytometry, respectively. Median relative difference (MRD) was calculated for each immunological variable. For values greater than reference, MRD should be a positive number and for values that are smaller, MRD should be negative.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>OUTCOMES</b>
</p>
<p>The severe pneumonia observed in SARS-CoV-2/HIV-1-positive patient under protease inhibitors was reversed by a 7-days hydroxychloroquine therapy. At the end of treatment, on day 7, patient reported resolution of fever, normalization of respiratory rate (14 breaths/min), and improved oxygen arterial pressure with a FiO2 of 30%. MRD values for IFNα/β and CD4 and CD8 T cells expressing CD38 and/or HLA-DR found in SARS-CoV-2-/HIV-1-coinfected woman were approximatively equal to 0 when refereed respectively to HIV-1-positive female patients [MRDs IFNα/β: median -0.2545 (range: -0.5/0.1); T cells: median -0.11 (range: -0.8/1.3)] and ≥ 6 when referred to healthy individuals [MRDs IFNα/β: median 28.45 (range: 15/41.9); T cells: median 10 (range 6/22)].</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>LESSONS</b>
</p>
<p>These results indicate that SARS-CoV-2 infection in HIV-1-positive female patient was associated with increased levels of IFNα/β-mRNAs and T cell activation compared to healthy individuals.</p>
</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">32899009</PMID>
<DateCompleted>
<Year>2020</Year>
<Month>09</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1536-5964</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>99</Volume>
<Issue>36</Issue>
<PubDate>
<Year>2020</Year>
<Month>Sep</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>Medicine</Title>
<ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
</Journal>
<ArticleTitle>Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.</ArticleTitle>
<Pagination>
<MedlinePgn>e21803</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000021803</ELocationID>
<Abstract>
<AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Complex immune dysregulation in interferon (IFN) and T cell response has been observed in human immunodeficiency virus (HIV-1)-infected patients as well as in coronavirus disease-2019 (COVID-19) patients. However, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/HIV-1 coinfection has been described in only few cases worldwide and no data are available on immunological outcomes in HIV-1-patients infected with SARS-CoV-2. Hence, this study aims to compare type I IFN response and T cell activation levels between a SARS-CoV-2/HIV-1-coinfected female patient and age-matched HIV-1-positive or uninfected women.</AbstractText>
<AbstractText Label="PATIENT CONCERNS" NlmCategory="UNASSIGNED">A 52-year-old woman diagnosed with SARS-CoV-2/HIV-1 coinfection, ten HIV-1-positive women and five age-matched-healthy individuals were enrolled in this study.</AbstractText>
<AbstractText Label="DIAGNOSES" NlmCategory="UNASSIGNED">SARS-CoV-2 infection caused severe pneumonia in the second week of illness in HIV-1-positive patient under protease inhibitors. Chest high-resolution computed tomography images of the SARS-CoV-2/HIV-1-coinfected patient showed bilateral ground-glass opacities.</AbstractText>
<AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">SARS-CoV-2/HIV-1-coinfected female patient under darunavir/cobicistat regimen received a 7-days hydroxychloroquine therapy. Analysis of IFNα/β mRNA levels and CD4 and CD8 T cell (CD38, human leukocyte antigen-DR [HLA-DR], CD38 HLA-DR) frequencies were performed by RT/real-time PCR assays and flow cytometry, respectively. Median relative difference (MRD) was calculated for each immunological variable. For values greater than reference, MRD should be a positive number and for values that are smaller, MRD should be negative.</AbstractText>
<AbstractText Label="OUTCOMES" NlmCategory="RESULTS">The severe pneumonia observed in SARS-CoV-2/HIV-1-positive patient under protease inhibitors was reversed by a 7-days hydroxychloroquine therapy. At the end of treatment, on day 7, patient reported resolution of fever, normalization of respiratory rate (14 breaths/min), and improved oxygen arterial pressure with a FiO2 of 30%. MRD values for IFNα/β and CD4 and CD8 T cells expressing CD38 and/or HLA-DR found in SARS-CoV-2-/HIV-1-coinfected woman were approximatively equal to 0 when refereed respectively to HIV-1-positive female patients [MRDs IFNα/β: median -0.2545 (range: -0.5/0.1); T cells: median -0.11 (range: -0.8/1.3)] and ≥ 6 when referred to healthy individuals [MRDs IFNα/β: median 28.45 (range: 15/41.9); T cells: median 10 (range 6/22)].</AbstractText>
<AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">These results indicate that SARS-CoV-2 infection in HIV-1-positive female patient was associated with increased levels of IFNα/β-mRNAs and T cell activation compared to healthy individuals.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>d'Ettorre</LastName>
<ForeName>Gabriella</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Recchia</LastName>
<ForeName>Gregorio</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ridolfi</LastName>
<ForeName>Marco</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Siccardi</LastName>
<ForeName>Guido</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pinacchio</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Innocenti</LastName>
<ForeName>Giuseppe Pietro</ForeName>
<Initials>GP</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Santinelli</LastName>
<ForeName>Letizia</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Frasca</LastName>
<ForeName>Federica</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bitossi</LastName>
<ForeName>Camilla</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ceccarelli</LastName>
<ForeName>Giancarlo</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Borrazzo</LastName>
<ForeName>Cristian</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Antonelli</LastName>
<ForeName>Guido</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Microbiology and Virology Unit, Hospital "Policlinico Umberto I", Sapienza University, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Scagnolari</LastName>
<ForeName>Carolina</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mastroianni</LastName>
<ForeName>Claudio Maria</ForeName>
<Initials>CM</Initials>
<AffiliationInfo>
<Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Medicine (Baltimore)</MedlineTA>
<NlmUniqueID>2985248R</NlmUniqueID>
<ISSNLinking>0025-7974</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9008-11-1</RegistryNumber>
<NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Medicine (Baltimore). 2020 Oct 16;99(42):e22949</RefSource>
<PMID Version="1">33080768</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D044966" MajorTopicYN="N">Anti-Retroviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>9</Month>
<Day>9</Day>
<Hour>1</Hour>
<Minute>2</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>9</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">32899009</ArticleId>
<ArticleId IdType="doi">10.1097/MD.0000000000021803</ArticleId>
<ArticleId IdType="pii">00005792-202009040-00021</ArticleId>
<ArticleId IdType="pmc">PMC7478511</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Health Equity. 2020 Apr 17;4(1):139-141</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32368712</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2020 May 30;395(10238):1695-1704</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32401715</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Med. 2020 Apr;26(4):453-455</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32284614</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Virol. 2020 Jul;128:104450</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32464309</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Med Microbiol Immunol. 2019 Oct;208(5):679-691</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">30564919</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet HIV. 2020 May;7(5):e314-e316</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32304642</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infection. 2020 Oct;48(5):681-686</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32394344</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect. 2013 Dec;67(6):606-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24096239</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Med Virol. 2020 Jun;92(6):529-530</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32160316</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32379955</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32407669</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunol Rev. 2013 Jul;254(1):78-101</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23772616</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Am Coll Cardiol. 2020 Jun 2;75(21):2746-2748</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32330545</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cytokine Growth Factor Rev. 2018 Apr;40:19-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">29576284</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Infect Dis. 2020 Jul;96:148-150</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32335339</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cytokine. 2019 Aug;120:273-281</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">30910260</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Expert Rev Respir Med. 2016 Apr;10(4):463-472</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26918376</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2020 Jul 28;71(15):762-768</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32161940</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2020 Nov 19;71(16):2276-2278</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32407467</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Thorax. 2004 Mar;59(3):252-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14985565</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2020 May 28;181(5):1036-1045.e9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32416070</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2020 Sep 12;71(6):1400-1409</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32270184</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Discov. 2020 May 4;6:31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32377375</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Racial Ethn Health Disparities. 2020 Jun;7(3):398-402</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32306369</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Sex Differ. 2020 May 1;11(1):23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32357901</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C64 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000C64 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32899009
   |texte=   Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32899009" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1
Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021